Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Fanucchi, L.; Springer, S. A.; and Korthuis, P. T. Current HIV/AIDS reports, 16(1):1–6, February, 2019.
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV [link]Paper  doi  abstract   bibtex   
Purpose of Review Recent HIVoutbreaks have occurred as a result of the current US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone, buprenorphine, and extended-release naltrexone is essential to achieving optimal HIV treatment outcomes including viral suppression and retention in treatment. This review describes the pharmacology of MOUD with specific attention to interactions with antiretroviral therapy, and to the effect of MOUD on HIV treatment outcomes. Recent Findings Methadone and buprenorphine both improve HIV viral suppression, adherence to antiretroviral therapy, and overall mortality for persons with opioid use disorder (OUD). Extended-release naltrexone has been most extensively studied in persons with HIV leaving incarcerated settings, and improves HIV viral suppression in that context. Summary Strategies that integrate MOUD and HIV treatment are crucial to optimize viral suppression. The differing pharmacokinetic and delivery characteristics of these MOUD offer diverse options. Given the chronic and relapsing nature of both HIV and OUD, long-term approaches are required.
@article{fanucchi_medications_2019,
	title = {Medications for {Treatment} of {Opioid} {Use} {Disorder} among {Persons} {Living} with {HIV}},
	volume = {16},
	issn = {1548-3568},
	url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420833/},
	doi = {10.1007/s11904-019-00436-7},
	abstract = {Purpose of Review
Recent HIVoutbreaks have occurred as a result of the current US opioid epidemic. Providing medications for opioid use disorder (MOUD) with methadone, buprenorphine, and extended-release naltrexone is essential to achieving optimal HIV treatment outcomes including viral suppression and retention in treatment. This review describes the pharmacology of MOUD with specific attention to interactions with antiretroviral therapy, and to the effect of MOUD on HIV treatment outcomes.

Recent Findings
Methadone and buprenorphine both improve HIV viral suppression, adherence to antiretroviral therapy, and overall mortality for persons with opioid use disorder (OUD). Extended-release naltrexone has been most extensively studied in persons with HIV leaving incarcerated settings, and improves HIV viral suppression in that context.

Summary
Strategies that integrate MOUD and HIV treatment are crucial to optimize viral suppression. The differing pharmacokinetic and delivery characteristics of these MOUD offer diverse options. Given the chronic and relapsing nature of both HIV and OUD, long-term approaches are required.},
	number = {1},
	urldate = {2019-05-12},
	journal = {Current HIV/AIDS reports},
	author = {Fanucchi, Laura and Springer, Sandra A. and Korthuis, P. Todd},
	month = feb,
	year = {2019},
	pmid = {30684117},
	pmcid = {PMC6420833},
	keywords = {important},
	pages = {1--6}
}
Downloads: 0